NIPH Clinical Trials Search

A Retrospective Study of Safety and Efficacy for Re-treatment of Brentuximab-Vedotin (BV) in Patients With Relapsed/Refractory (R/R) classical Hodgkin Lymphoma (cHL)/ systemic Anaplastic Large-cell Lymphoma (sALCL)

Basic Information

Recruitment status	Complete: follow-up complete
Health condition(s) or Problem(s) studied	CD30 positive cHL or sALCL
Date of first enrollment	2017/12/15
Target sample size	20
Countries of recruitment	Japan
Study type	Observational
Intervention(s)

Outcome(s)

Primary Outcome	Number of Participants who Experience at least one Treatment-Emergent Adverse Events (TEAE), Overall response rate (ORR)
Secondary Outcome	Complete response rate (CR rate), Progression-free survival (PFS), Duration of response (DOR), Time to treatment failure (TTF)

Key inclusion & exclusion criteria

Age minimum	Not applicable
Age maximum	Not applicable
Gender	Male and Female
Include criteria
Exclude criteria	1. Patients judged by the investigator or subinvestigator to be ineligible for enrollment in the study (such as patients who may be coerced to give consent)